GT19870 / Kintor Pharma - LARVOL DELTA

Discovery and evaluation of GT19870, a GSPT1/Myc molecular glue drug (MGD) with oral bioavailability for targeting c-Myc and n-Myc-addictive blood cancer and solid tumors (AACR 2024) - "This novel MGD has been demonstrated target-engaged antitumor activities in vitro and in vivo with selectivity of c-Myc degradation in c-Myc-addictive cancer cells as compared to growth factor-stimulated TF-1 cells and CD3/CD28 activated PBMC. GT19870 has been progressing IND enabling stage."

Acute Myelogenous Leukemia • Brain Cancer • Breast Cancer • CNS Tumor • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Lung Cancer • Metastatic Castration-Resistant Prostate Cancer • Neuroblastoma • Oncology • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer • GSPT1 • MYC • MYCN

AACR 2024 Foreight | Three Oncology Studies From Kintor Pharma Selected (Kintor Pharma Press Release) - "In AACR 2024, one study of drug candidate GT0486 and two pre-clinical studies (including an anti-PD-1/ALK-1 bispecific antibody Nivo813 and a molecular glue GT19870) from Kintor Pharma are selected. It demonstrates high research and development value of drug and pre-clinical studies, also signifies that the company’s innovative capabilities and potential for drug development have been internationally recognized."

Preclinical • Solid Tumor